CWA Asset Management Group LLC Has $686,000 Holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

CWA Asset Management Group LLC boosted its position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 92.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 85,267 shares of the biotechnology company's stock after buying an additional 40,878 shares during the period. CWA Asset Management Group LLC owned approximately 0.06% of Aurinia Pharmaceuticals worth $686,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. SBI Securities Co. Ltd. acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter worth about $25,000. GF Fund Management CO. LTD. bought a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth about $27,000. Tower Research Capital LLC TRC lifted its holdings in shares of Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth about $31,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 56.1% in the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock worth $39,000 after acquiring an additional 1,744 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Price Performance

Shares of AUPH stock traded down $0.15 on Friday, reaching $7.77. The company had a trading volume of 1,199,723 shares, compared to its average volume of 1,328,417. The stock has a market capitalization of $1.05 billion, a PE ratio of 27.75 and a beta of 1.15. The company has a quick ratio of 5.26, a current ratio of 5.93 and a debt-to-equity ratio of 0.16. Aurinia Pharmaceuticals Inc has a one year low of $5.20 and a one year high of $10.67. The business's 50-day moving average is $8.04 and its 200 day moving average is $8.21.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its earnings results on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, topping analysts' consensus estimates of $0.08 by $0.08. The firm had revenue of $62.47 million during the quarter, compared to analysts' expectations of $61.06 million. Aurinia Pharmaceuticals had a net margin of 16.11% and a return on equity of 14.27%. Equities research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, March 27th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.